menu
    • menu
    [{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase I","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Immunology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Immunology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Immunology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2022","type":"Not Applicable","leadProduct":"ATA188","moa":"T lymphocyte","graph1":"Neurology","graph2":"Phase I\/ Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Atara Biotherapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Cell and Gene therapy","year":"2023","type":"Not Applicable","leadProduct":"ATA188","moa":"","graph1":"Neurology","graph2":"Phase II","graph3":"Atara Biotherapeutics","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Atara Biotherapeutics \/ Not Applicable","highestDevelopmentStatusID":"8","companyTruncated":"Atara Biotherapeutics \/ Not Applicable"}]

    Find Clinical Drug Pipeline Developments & Deals for ATA188

    Menu

    ATA188

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics Announces Primary Analysis Data from Phase 2 EMBOLD Clinical Trial of ATA188 in Non-Acti...

                            Details : ATA188 (Allogeneic EBV T-cell), Atara’s investigational off-the-shelf T-cell candidate, has the potential to target EBV-infected B cells and plasma cells in the central nervous system that may catalyze autoimmune responses and MS pathophysiology.

                            Brand Name : ATA188

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 08, 2023

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics to Present Recent Progress and Key Upcoming Catalysts at the 40th Annual J.P. Morgan Hea...

                            Details : ATA188 (Allogeneic EBV T-cell), off-the-shelf T-cell candidate, has the potential to target EBV-infected B cells and plasma cells in the central nervous system that may catalyze autoimmune responses and MS pathophysiology.

                            Brand Name : ATA188

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            January 10, 2022

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Study Phase : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics Presents New Magnetization Transfer Ratio Imaging Data and Two-Year Clinical Data from t...

                            Details : One patient with secondary progressive multiple sclerosis (SPMS) who had achieved SDI experienced a non-treatment related relapse at 18 months, occurring approximately six months after the last ATA188 dose, and elected to discontinue the study.

                            Brand Name : ATA188

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            October 13, 2021

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA188

                            Therapeutic Area : Immunology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics to Present Phase 1 Study Update of ATA188 in Progressive Multiple Sclerosis at ECTRIMS 2...

                            Details : ATA188, Atara’s investigational off-the-shelf T-cell candidate, has the potential to target EBV-infected B cells and plasma cells in the central nervous system that may catalyze autoimmune responses and MS pathophysiology.

                            Brand Name : ATA188

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 29, 2021

                            Lead Product(s) : ATA188

                            Therapeutic Area : Immunology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics to Present Data from its Phase1a Study of ATA188 for Progressive Forms of Multiple Scler...

                            Details : Throughout the entire Phase 1a and OLE study, nine of the 16 patients who entered the OLE demonstrated sustained disability improvement (SDI) with ATA188 treatment (seven achieved SDI in the first twelve months and two during the OLE).

                            Brand Name : ATA188

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            November 15, 2020

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics Announces Positive Results of Phase 1a Study of ATA188 in MS Patients with Sustained Dis...

                            Details : The data indicated that ATA188 was well tolerated in all four dose cohorts; patients who achieved sustained disability improvements (SDI) time point retained it at all subsequent time points; a higher proportion of patients showed SDI with increasing dos...

                            Brand Name : ATA188

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 11, 2020

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics to Present 12-Month Data from All Four Cohorts in the Phase 1a Study of ATA188 in Progre...

                            Details : Company will present for the first time 12-month data from all four cohorts in the Phase 1a study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS) at MSVirtual2020: 8th Joint ACTRIMS-ECTRIMS Meeting.

                            Brand Name : ATA188

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            September 01, 2020

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics Enrolled First Patient in Placebo-Controlled Study of Allogeneic T-cell Therapy ATA188 i...

                            Details : Based on the Phase 1a study findings showing sustained disability improvements in active MS patients, the Phase 1b study will assess clinical outcomes including disability measures, physical and cognitive performance, biomarkers and MRI imaging, as well ...

                            Brand Name : ATA188

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            June 17, 2020

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed

                            Atara Biotherapeutics

                            U.S.A arrow
                            euroPLX 86 Munich
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Atara Biotherapeutics to Present Late-Breaking ATA188 Data in Progressive Multiple Sclerosis at 2020 and EAN V...

                            Details : Company will present updated safety and efficacy data from its ongoing Phase 1 study of ATA188 for the treatment of progressive forms of multiple sclerosis (MS) in a late-breaking e-poster presentation at the 6th European Academy of Neurology (EAN) Annua...

                            Brand Name : ATA188

                            Molecule Type : Cell and Gene therapy

                            Upfront Cash : Not Applicable

                            May 19, 2020

                            Lead Product(s) : ATA188

                            Therapeutic Area : Neurology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth